TABLE 7.
Drug combinationa | Mean synergy vol ± SD (μM2 %)b | Mean antagonism vol ± SD (μM2 %)b | Interaction |
---|---|---|---|
Glecaprevir + IFN-α | 15 ± 1.9 | −1.1 ± 0.2 | Additive |
Glecaprevir + RBV | 24 ± 4.9 | −2.7 ± 0.2 | Additive |
Glecaprevir + pibrentasvir | 73 ± 17 | −1.9 ± 0.4 | Moderate synergy |
IFN-α, interferon alpha; RBV, ribavirin. Pibrentasvir is an HCV NS5A inhibitor.
Values were determined in ≥3 independent experiments.